VALHI DECLARES QUARTERLY DIVIDEND

March 6, 2025

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) announced today that its board of directors has declared a regular quarterly dividend of eight cents ($0.08) per share on its common stock, payable on March 28, 2025 to stockholders of record at the close of business on March 17, 2025.

Valhi, Inc. is engaged in the chemicals (TiO₂), component products (security products and recreational marine components) and real estate management and development industries.

* * * * *

Investor Relations Contact

Bryan A. Hanley
Senior Vice President and Treasurer
Tel. 972-233-1700

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Clarus Reports Fourth Quarter and Full Year 2024 Results

Global Ship Lease Declares Quarterly Dividend on its 8.75% Series B Cumulative Redeemable Perpetual Preferred Shares

VALHI DECLARES QUARTERLY DIVIDEND

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Topics

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Holding(s) in Company

C3is Inc. announces the date for the release of the fourth quarter and full year 2024 financial and operating results

Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements

Related Articles

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Company

Headlines

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Newsletter